Metoprolol Dose Escalation for Rate Control in Thyrotoxicosis

Initial Oral Dosing

• The American College of Endocrinology and the American Association of Clinical Endocrinologists recommend starting oral metoprolol tartrate 25 mg–50 mg every 6 hours in patients with symptomatic thyrotoxicosis who have a resting heart rate > 90 bpm or co‑existing cardiovascular disease, allowing assessment of tolerance while providing initial symptom relief. 1

Intravenous Administration for Severe Tachycardia

• For patients with severe tachycardia or persistent symptoms despite oral therapy, the American Heart Association suggests an intravenous metoprolol bolus of 5 mg over 2 minutes, repeatable every 5 minutes up to a total of 15 mg, followed by transition to oral therapy 15 minutes after the final IV dose. 2, 3

Dose‑Escalation Protocol

Target Heart‑Rate Goals

• The American College of Cardiology advises escalating the dose until a resting heart rate of 50–60 bpm is achieved or dose‑limiting side effects appear. 4, 2

Maximum Tolerated Dose and Transition

• Titration may be continued to a daily dose of up to 200 mg (or higher if needed) as tolerated, converting from q6‑hour dosing to twice‑daily metoprolol tartrate or once‑daily metoprolol succinate over 2–3 days. 5, 6

Rationale for High Doses

• In thyrotoxicosis, beta‑blocker doses frequently exceed typical cardiovascular dosing because very high doses are often required to control symptoms and maintain heart rate near the upper limit of normal. 1

Monitoring and Safety

• Frequent heart‑rate and blood‑pressure checks are recommended during dose escalation to detect overtreatment or adverse effects. 4, 2
• Continuous ECG monitoring should be employed when using the intravenous formulation to promptly identify arrhythmias. 2, 3
• Auscultation for pulmonary rales and bronchospasm is advised, especially as higher doses may reduce β‑1 selectivity. 4, 2

Special Considerations

• In patients with bronchospastic disease, smaller metoprolol doses administered three times daily are preferred over larger twice‑daily doses to avoid high peak plasma concentrations and reduce the risk of bronchospasm. 1

Alternative Rate‑Control Options

• When beta‑blockers are contraindicated or ineffective, oral calcium‑channel blockers such as verapamil or diltiazem may be employed for rate control; however, beta‑blockers remain the first‑line therapy for thyrotoxicosis. 1